What is BCAX stock price today?

BCAX (Bicara Therapeutics Inc) stock is trading at $21.47 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is BCAX stock going up or down today?

BCAX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy BCAX stock now?

The decision to buy BCAX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is BCAX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for BCAX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is BCAX stock overvalued or undervalued?

Use our DCF valuation calculator to determine if BCAX is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is BCAX's P/E ratio?

P/E ratio data for BCAX will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is BCAX's market cap?

BCAX (Bicara Therapeutics Inc) has a market capitalization of $1.41 billion, making it a small-cap stock.

What is BCAX's price to book ratio?

BCAX trades at a price-to-book (P/B) ratio of 3.34, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does BCAX pay dividends?

BCAX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is BCAX's dividend yield?

BCAX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is BCAX stock a good long-term investment?

BCAX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is BCAX's revenue growth rate?

Revenue growth data for BCAX is available on our dashboard with detailed financial statement analysis.

Profitability metrics for BCAX are available on our dashboard with complete income statement analysis.

What are the risks of investing in BCAX?

Key risks for BCAX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does BCAX compare to its competitors?

Compare BCAX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize BCAX's performance and positioning.

What is BCAX's stock price target for 2026?

Our AI model provides price targets for BCAX based on fundamental analysis: Bull case $27.91 (+30%), Base case $24.69 (+15%), Bear case $19.32 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about BCAX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for BCAX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is BCAX's next earnings report?

BCAX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

BCAX - Bicara Therapeutics Inc

NYSE * Health Care * Biotechnology

$21.47

+$0.97 (+4.73%)

About Bicara Therapeutics Inc

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

BCAX Key Statistics

Market Cap

$1.41B

P/B Ratio

3.34

EPS

$-2.52

Employees

103

How BCAX Compares to Peers

BCAX is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
BCAX(This stock)	$1.41B	N/A	0%	0.0%	-
AMGNAmgen Inc	$187.56B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.41B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$111.43B	28.7	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$80.54B	18.4	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.2	-0%	0.1%	vs BIIB

Bicara Therapeutics Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: www.bicara.com
Sector: Health Care
Industry: Biotechnology

Data Updated: April 4, 2026 at 6:45 PM EDT

Ready to invest in BCAX?

Commission-free trading available. Affiliate links.

BCAX Lician Score

5% confidence

4.0/10

Neutral

BCAX has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates BCAXacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

BCAX Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for BCAX

Dashboard

Enter a ticker to analyze